Claims for Patent: 7,411,050

Summary for Patent: 7,411,050

Title:	Monoclonal blocking antibody to human RANKL
Abstract:	Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL.
Inventor(s):	Anderson; Dirk M. (Seattle, WA)
Assignee:	Immunex Corporation (Thousand Oaks, CA)
Application Number:	10/802,133
Patent Claims:	1. An isolated blocking antibody that binds to a human RANKL polypeptide as set forth in SEQ ID NO:13 and inhibits the binding of the human RANKL polypeptide to a human RANK polypeptide as shown in SEQ ID NO:6. 2. The blocking antibody of claim 1 that is a monoclonal antibody. 3. An isolated blocking antibody that binds to a fragment of a human RANKL polypeptide as shown in SEQ ID NO:13 and inhibits the binding of the human RANKL polypeptide to a human RANK polypeptide as shown in SEQ ID NO:6, wherein the fragment is selected from the group consisting of a) an extracellular domain comprising amino acids 69-317 of SEQ ID NO:13, and b) a receptor binding domain comprising amino acids 162-317 of SEQ ID NO:13. 4. The blocking antibody of claim 3 that is a monoclonal antibody.

Details for Patent 7,411,050

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010		2016-12-23
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010		2016-12-23

International Patent Family for US Patent 7,411,050

Country	Patent Number	Estimated Expiration
Austria	401404
Austria	412746
Austria	497001
Austria	517916
Australia	3988899